[Association of CHRNA4 gene polymorphisms with response to antidepressant among ethnic Han Chinese]
Jianying Yu1, Zaiquan Dong, Tao Yu
1Psychological Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. sunxueli58@163.com.
Objective:
To assess the association of single nucleotide polymorphisms (SNPs) CHRNA4 gene with response to selective serotonin re-uptake inhibitors (SSRIs) for the treatment of major depressive disorder (MDD).
Methods:
For 304 patients receiving drug treatment for major depression, 2 SNPs, namely rs4522666 and rs4603829, of the CHRNA4 gene were determined by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry. HAMD-17 was adopted as the primary rating tool to evaluate the severity of depression on the baseline and at the end of 1st, 2nd, 4th and 6th weeks treatment.
Results:
The frequency of GG genotype/G allele for rs4522666 differed significantly from that of TT and GT genotypes/T allele between responders and non-responders (P=0.015 and P=0.006, respectively). No significant difference was found in genotypic and allelic frequencies of rs4603829 between the two groups (P> 0.05).
Conclusion:
SNPs of the CHRNA4 gene may play an important role in the response to antidepressant drugs among ethnic Han Chinese with MDD.
More Related Videos
11:31Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting
Published on: November 30, 2015
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Single Nucleotide Polymorphisms-SNPs
Antidepressant Drugs: MAOIs and Other Agents
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
